|
| 37462445 | TERT Promoter Mutations Frequency Across Race, Sex, and Cancer Type. | Oncologist | 2024 |
| 37914579 | Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. | Eur Urol Oncol | 2024 |
| 37487814 | Changes in Prostate-specific Antigen Screening after the 2018 United States Preventive Services Task Force Recommendations and Through the COVID-19 Pandemic. | Eur Urol Oncol | 2024 |
| 37487813 | Stereotactic Magnetic Resonance-guided Adaptive Radiation Therapy for Localized Kidney Cancer: Early Outcomes from a Prospective Phase 1 Trial and Supplemental Cohort. | Eur Urol Oncol | 2024 |
| 37852850 | Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial. | Eur Urol | 2024 |
| 37589219 | Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma. | Oncologist | 2024 |
| 37950901 | A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell Carcinoma. | Oncologist | 2024 |
| 38060202 | PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti-PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients. | Clin Cancer Res | 2024 |
| 38049623 | Author Correction: Liquid biopsy epigenomic profiling for cancer subtyping. | Nat Med | 2024 |
| 38048064 | The 5th Kidney Cancer Research Summit: Research Accelerating Cures for Renal Cell Carcinoma in 2023. | Oncologist | 2024 |
| 35945133 | CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). | Clin Genitourin Cancer | 2023 |
| 37865722 | Liquid biopsy epigenomic profiling for cancer subtyping. | Nat Med | 2023 |
| 37526095 | Plain language summary looking at how long side effects last after treatment with axitinib is stopped in people with advanced renal cell carcinoma. | Future Oncol | 2023 |
| 37664025 | Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. | Front Oncol | 2023 |
| 37524096 | Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial. | Lancet | 2023 |
| 37482537 | Evaluation of statin use and renal cell carcinoma risk identifies sex-specific associations with RCC subtypes. | Acta Oncol | 2023 |
| 37586773 | Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases. | J Immunother Cancer | 2023 |
| 37882432 | LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma. | Future Oncol | 2023 |
| 37577497 | A genetic basis for cancer sex differences revealed in Xp11 translocation renal cell carcinoma. | bioRxiv | 2023 |
| 37541245 | Chromophobe renal cell carcinoma | Cancer Cell | 2023 |
| 37498602 | Disparities in Travel-Related Barriers to Accessing Health Care From the 2017 National Household Travel Survey. | JAMA Netw Open | 2023 |
| 37729872 | Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer states. | Cell Rep Med | 2023 |
| 37563779 | Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors. | J Natl Cancer Inst | 2023 |
| 37192435 | Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium. | J Clin Oncol | 2023 |
| 37290461 | Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. | Lancet | 2023 |
| 37085424 | Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell Carcinoma. | Eur Urol | 2023 |
| 37084289 | Visceral Metastasis Predicts Response to New Hormonal Agents in Metastatic Castration-Sensitive Prostate Cancer. | Oncologist | 2023 |
| 37285719 | COVID-19 in cancer patients: update from the joint analysis of the ESMO-CoCARE, BSMO, and PSMO international databases. | ESMO Open | 2023 |
| 37414704 | Oligometastatic Bladder Cancer: Defining a Novel Entity. | Eur Urol | 2023 |
| 37279009 | Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma. | Cancer Immunol Res | 2023 |
| 37011650 | Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study. | Lancet Oncol | 2023 |
| 37407357 | Emerging Biomarkers of Response to Systemic Therapies in Metastatic Clear Cell Renal Cell Carcinoma. | Hematol Oncol Clin North Am | 2023 |
| 37104931 | Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma. | ESMO Open | 2023 |
| 37302348 | COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular disease. | Transl Oncol | 2023 |
| 36967358 | Corrigendum to "Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma" [Eur Urol 2023]. | Eur Urol | 2023 |
| 37330344 | Renal Cell Cancer. | Hematol Oncol Clin North Am | 2023 |
| 37163623 | Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. | N Engl J Med | 2023 |
| 37294085 | Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial. | Int J Cancer | 2023 |
| 36858721 | Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. | Lancet Oncol | 2023 |
| 36853925 | Efficacy of Grignard Pure to Inactivate Airborne Phage MS2, a Common SARS-CoV-2 Surrogate. | Environ Sci Technol | 2023 |
| 36812889 | Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma. | Cell Rep Med | 2023 |
| 36517393 | The Natural History of Renal-Cell Carcinoma with Sarcomatoid Differentiation, a Stage-by-Stage Analysis. | Clin Genitourin Cancer | 2023 |
| 36917626 | Patients' Perceptions Regarding the Relevance of Items Contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19. | Oncologist | 2023 |
| 36842942 | A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma. | Eur Urol Oncol | 2023 |
| 36712083 | Integrative Analysis of Germline Rare Variants in Clear and Non-Clear Cell Renal Cell Carcinoma. | medRxiv | 2023 |
| 36712053 | Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer states. | bioRxiv | 2023 |
| 36576173 | Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial. | Oncologist | 2023 |
| 36640141 | Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas. | Oncologist | 2023 |
| 36573926 | Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. | J Urol | 2023 |
| 36681680 | Epigenomic charting and functional annotation of risk loci in renal cell carcinoma. | Nat Commun | 2023 |